Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management.

COVID-19 OR, odds ratios SARS-CoV-2 TE, telogen effluvium TR, trichodynia hair loss hair shedding multicentric study scalp allodynia telogen effluvium trichodynia

Journal

JAAD international
ISSN: 2666-3287
Titre abrégé: JAAD Int
Pays: United States
ID NLM: 101774762

Informations de publication

Date de publication:
Dec 2021
Historique:
accepted: 21 07 2021
pubmed: 10 8 2021
medline: 10 8 2021
entrez: 9 8 2021
Statut: ppublish

Résumé

The cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also been reported. To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to the other signs and symptoms of the disease. Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms were questioned about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms. Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of the patients and trichodynia in 58.4%. Trichodynia was associated with telogen effluvium in 42.4% of the cases and anosmia and ageusia in 66.1% and 44.1% of the cases, respectively. In majority (62.5%) of the patients, the hair signs and symptoms started within the first month after COVID-19 diagnosis, and in 47.8% of the patients, these started after 12 weeks or more. The recruitment of patients in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities. The severity of postviral telogen effluvium observed in patients with a history of COVID-19 infection may be influenced by COVID-19 severity. We identified early-onset (<4 weeks) and late-onset (>12 weeks) telogen effluvium.

Sections du résumé

BACKGROUND BACKGROUND
The cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also been reported.
OBJECTIVE OBJECTIVE
To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to the other signs and symptoms of the disease.
METHODS METHODS
Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms were questioned about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms.
RESULTS RESULTS
Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of the patients and trichodynia in 58.4%. Trichodynia was associated with telogen effluvium in 42.4% of the cases and anosmia and ageusia in 66.1% and 44.1% of the cases, respectively. In majority (62.5%) of the patients, the hair signs and symptoms started within the first month after COVID-19 diagnosis, and in 47.8% of the patients, these started after 12 weeks or more.
LIMITATIONS CONCLUSIONS
The recruitment of patients in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities.
CONCLUSION CONCLUSIONS
The severity of postviral telogen effluvium observed in patients with a history of COVID-19 infection may be influenced by COVID-19 severity. We identified early-onset (<4 weeks) and late-onset (>12 weeks) telogen effluvium.

Identifiants

DOI: 10.1016/j.jdin.2021.07.006 PMID: 34368790 PMC: PMC8328568
pubmed: 34368790
doi: 10.1016/j.jdin.2021.07.006
pii: S2666-3287(21)00056-0
pmc: PMC8328568
doi:

Types de publication

Journal Article

Langues

eng

Pagination

11-18

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc.

Déclaration de conflit d'intérêts

Dr Tosti is a consultant for DS Laboratories, Monat Global, Almirall, Tirthy Madison, Eli Lilly, Leo Pharmaceuticals, Bristol Myers Squibb, and P&G. Drs Starace, Lorizzo, Sechi, Alessandrini, Carpanese, Bruni, Vara, Apalla, Asz-Sigall, Barruscotti, Camacho, Doche, Estrada, Dhurat, Gavazzoni, Grimalt, Harries, Ioannidis, McMichael, Melo, Oliveira, Ovcharenko, Pirmez, Ramot, Rudnicka, Shapiro, Silyuk, Sinclair, Vano-Galvan, and Piraccini have no conflicts of interest to declare.

Références

Am J Clin Dermatol. 2020 Oct;21(5):627-639
pubmed: 32865778
Arch Dermatol. 1961 Feb;83:175-98
pubmed: 13756813
Drugs Real World Outcomes. 2016 Mar;3(1):1-6
pubmed: 27747798
Exp Dermatol. 2021 Feb;30(2):288-290
pubmed: 33316115
J Eur Acad Dermatol Venereol. 2009 Jun;23(6):733-4
pubmed: 19281607
Reumatologia. 2015;53(4):207-12
pubmed: 27407249
Eur J Dermatol. 2002 Sep-Oct;12(5):432-8
pubmed: 12370129
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAAD Int. 2021 Mar;2:119-133
pubmed: 33479703
Skin Appendage Disord. 2016 Sep;2(1-2):39-44
pubmed: 27843921
J Interferon Cytokine Res. 1997 Mar;17(3):151-7
pubmed: 9085940
J Cosmet Dermatol. 2021 Apr;20(4):1088-1090
pubmed: 33387387
J Am Acad Dermatol. 2020 Jul;83(1):280-285
pubmed: 32305439
Indian J Dermatol Venereol Leprol. 2009 Jan-Feb;75(1):20-7; quiz 27-8
pubmed: 19172026
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Int J Dermatol. 2003 Sep;42(9):691-3
pubmed: 12956679
Aust J Gen Pract. 2020 Aug 26;49:
pubmed: 33051638
J Am Acad Dermatol. 2021 Mar;84(3):773-775
pubmed: 33310111
Int J Dermatol. 2021 Jan;60(1):122-124
pubmed: 33226117
Arch Dermatol. 1993 Mar;129(3):356-63
pubmed: 8447677
Australas J Dermatol. 2010 Aug;51(3):163-7
pubmed: 20695853
Life (Basel). 2021 Jan 02;11(1):
pubmed: 33401712
Dermatol Ther. 2020 Nov;33(6):e14096
pubmed: 32869938
Dermatol Ther. 2020 Nov;33(6):e13923
pubmed: 32594627
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e181-e183
pubmed: 33220124
Expert Opin Investig Drugs. 2001 Apr;10(4):673-8
pubmed: 11281817
Exp Dermatol. 1999 Aug;8(4):344-5
pubmed: 10439265
Dermatol Ther. 2020 Jul;33(4):e13648
pubmed: 32445237
Dermatology. 2002;205(4):374-7
pubmed: 12444334
Dermatol Ther. 2021 Jan;34(1):e14547
pubmed: 33190397
Dermatology. 1998;196(3):374-5
pubmed: 9621163
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e3-e4
pubmed: 32869377
Dermatol Ther. 2021 Mar;34(2):e14761
pubmed: 33405302

Auteurs

Michela Starace (M)

Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Matilde Iorizzo (M)

Private Dermatology Practice, Lugano/Bellinzona, Switzerland.

Andrea Sechi (A)

Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Aurora Maria Alessandrini (AM)

Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Miriam Carpanese (M)

Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Francesca Bruni (F)

Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Giulio Vara (G)

Radiology Unit, Policlinico Sant'Orsola, University of Bologna, Bologna, Italy.

Zoe Apalla (Z)

Second Department of Dermatology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Daniel Asz-Sigall (D)

Private Dermatology Practice, Mexico City, Mexico.

Stefania Barruscotti (S)

Department of Clinical-Surgical, Diagnostic and Pediatric Science, Institute of Dermatology, IRCCS Fondazione Policlinico San Matteo, University of Pavia, Pavia, Italy.

Francisco Camacho (F)

University of Seville, Medical-Surgical Dermatology Department, University Hospital, Seville, Spain.

Isabella Doche (I)

Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil.

Bruna Duque Estrada (BD)

Centro de Estudos dos Cabelos, Instituto de Dermatologia Prof. Rubem D Azulay, Rio de Janeiro, Brazil.

Rachita Dhurat (R)

Department of Dermatology, LTM Medical College & Hospital Sion, Mumbai, India.

Maria Fernanda Gavazzoni (MF)

Fluminense Federal University, Antônio Pedro Federal Hospital, Niterói Rio de Janeiro, Brazil.

Ramon Grimalt (R)

Facultat de Medicina i Ciencies de la Salut, UIC-Barcelona, Universitat Internacional de Catalunya, Sant Cugat del `Valles, Barcelona, Spain.

Matthew Harries (M)

Department of Dermatology, Salford Royal NHS Foundation Trust, Manchester, United Kingdom.

Dimitrios Ioannidis (D)

Department of Dermatology-Venereology, Aristotle University Medical School, Hospital for Skin and Venereal Diseases, Thessaloniki, Greece.

Amy McMichael (A)

Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.

Daniel Fernandes Melo (DF)

Department of Dermatology, University of State of Rio de Janeiro - UERJ, Rio de Janeiro, Brazil.

Rui Oliveira (R)

Trichology Unit, Dermatology Center CUF Descobertas Hospital, Lisbon, Portugal.

Yuliya Ovcharenko (Y)

Department of General and Clinical Immunology and Allergology, V.N. Karazin Kharkiv National University Medical School, Kharkiv, Ukraine.

Rodrigo Pirmez (R)

Centro de Estudos dos Cabelos, Instituto de Dermatologia Prof. Rubem D Azulay, Rio de Janeiro, Brazil.

Yuval Ramot (Y)

Department of Dermatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Lidia Rudnicka (L)

Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.

Jerry Shapiro (J)

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York City, New York.

Tatiana Silyuk (T)

Hair Treatment and Transplantation Center, Private Practice, Saint Petersburg, Russia.

Rodney Sinclair (R)

Sinclair Dermatology, Melbourne, Australia.

Antonella Tosti (A)

Fredric Brandt Endowed Professor of Dermatology, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida.

Sergio Vano-Galvan (S)

Dermatology Department, Ramon y Cajal Hospital, IRYCIS, University of Alcala, Madrid, Spain.

Bianca Maria Piraccini (BM)

Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Classifications MeSH